Last reviewed · How we verify

NCT04490720

The Efficacy Evaluation of Buckwheat Husk Extract on Cardiovascular Disease Risk Factors

Recruiting now NA Last updated 9 January 2025
What this trial tests

NA trial testing Placebo in Cardiovascular Diseases in 60 participants. Currently enrolling.

Timeline
24 November 2021
Primary endpoint
31 December 2025
28 February 2026

Quick facts

Lead sponsorTCI Co., Ltd.
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment60
Start date24 November 2021
Primary completion31 December 2025
Estimated completion28 February 2026
Sites1 location across Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

TCI Co., Ltd. — full company profile →

Who can join

Adults 20 to 65, any sex, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the efficacy evaluation of buckwheat husk extract on cardiovascular disease risk factors

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other TCI Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04490720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing